Young women more likely to be out of work sick than with children
Shares of SSR Mining Inc. ( NASDAQ:SSRM – Get Free Report ) (TSE:SSO) have earned an average rating of “Hold” from the six ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $5.18. SSRM has been the subject of a number of research reports. StockNews.com raised shares of SSR Mining from a “sell” rating to a “hold” rating in a report on Friday, December 13th. UBS Group increased their price objective on SSR Mining from $6.30 to $6.80 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Get Our Latest Stock Report on SSRM SSR Mining Stock Up 1.0 % Institutional Trading of SSR Mining A number of institutional investors and hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC acquired a new position in shares of SSR Mining during the second quarter valued at $3,289,000. National Bank of Canada FI boosted its stake in SSR Mining by 73.7% during the 2nd quarter. National Bank of Canada FI now owns 2,636,902 shares of the basic materials company’s stock valued at $11,815,000 after purchasing an additional 1,118,417 shares during the period. Two Sigma Advisers LP grew its position in SSR Mining by 16.2% in the 3rd quarter. Two Sigma Advisers LP now owns 3,320,384 shares of the basic materials company’s stock worth $18,860,000 after purchasing an additional 462,000 shares during the last quarter. Mackenzie Financial Corp increased its stake in shares of SSR Mining by 25.5% in the second quarter. Mackenzie Financial Corp now owns 883,581 shares of the basic materials company’s stock valued at $3,992,000 after purchasing an additional 179,601 shares during the period. Finally, Verition Fund Management LLC raised its holdings in shares of SSR Mining by 177.5% during the third quarter. Verition Fund Management LLC now owns 105,763 shares of the basic materials company’s stock valued at $601,000 after buying an additional 67,657 shares during the last quarter. 68.30% of the stock is owned by institutional investors and hedge funds. About SSR Mining ( Get Free Report SSR Mining Inc, together with its subsidiaries, engages in the operation, acquisition, exploration, and development of precious metal resource properties in the United States, Türkiye, Canada, and Argentina. The company explores for gold doré, copper, silver, lead, and zinc deposits. Its mines include the Çöpler, located in Erzincan province, Turkey; the Marigold, located in Nevada, the United States; the Seabee, located in Saskatchewan, Canada; and the Puna, located in Jujuy province, Argentina. Featured Articles Receive News & Ratings for SSR Mining Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SSR Mining and related companies with MarketBeat.com's FREE daily email newsletter .
Dive Into The Crypto Trifecta—Qubetics Enters Its 14th Presale Phase With A 10% Weekly Hike, While Bitcoin And Ethereum Eye Year-End HighsROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Kyverna Therapeutics, Inc. Investors To Secure Counsel Before Important Deadline In Securities Class Action – KYTX
Mayor vows to fight corruption allegations
Lawyer says ex-Temple basketball standout Hysier Miller met with NCAA for hours amid gambling probeThe Crypto Code Introduces Method for Reliable Crypto ProfitsEven with access to blockbuster obesity drugs, some people don't lose weightLuigi Mangione , the Ivy League tech hotshot accused of gunning down UnitedHealthcare’s CEO, was into 3D printing while studying at the University of Pennsylvania, his former pal told The Post Tuesday. “It’s funny, I recall him being into 3D printing in sophomore year,” said Matthew Levy, who lived next door to Mangione’s dorm room during their freshman year in 2016. “I mean, he was making much more innocent things then.” Mangione, 26, allegedly used what appeared to be a 3D-printed ghost gun in last week’s fatal shooting of Brian Thompson on a Manhattan sidewalk, cops have said. The gun, face masks and rambling writings linking Mangione to the ambush were allegedly found in his possession when he was captured at a McDonald’s in Altoona, Pennsylvania on Monday following a five-day manhunt, authorities said. Levy, who said he was friends with Mangione for three years in college, was among those shocked by his arrest. “He’s one of the last people I would have expected,” he told The Post. “He wasn’t particularly ideological. He never stood out as extreme.” About nine months ago, “something happened,” possibly linked to Mangione’s back injury “and he just cut everyone off, nobody could reach him,” Levy said. “I think that’s when his extremist views developed. He was a nice guy. He must have been radicalized at some point.” Details of Mangione’s 3D printing hobby and past life emerged as investigators continued to piece together a possible motive for the cold-blooded killing – including whether he was allegedly fueled by a vendetta against the medical industry after suffering from chronic back pain. At the time of his arrest, Mangione was allegedly carrying a handwritten document expressing anger with what he called “parasitic” health insurance companies and a disdain for corporate greed and power. He wrote that the US has the most expensive healthcare system in the world and that profits of major corporations continue to rise while “our life expectancy” does not, according to a law enforcement bulletin. In social media posts, Mangione also called “Unabomber” Ted Kaczynski a “political revolutionary,” the bulletin stated. Mangione was being held in a Pennsylvania lockup while fighting extradition to New York, where he is facing murder charges in Manhattan over Thompson’s slaying.
Incredible Aim! AI Robot Shatters Basketball Record.
Christmas Message 2024: From the CTUSABUnlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
